Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment
- PMID: 29391232
- PMCID: PMC5847475
- DOI: 10.1016/j.jconrel.2018.01.028
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment
Abstract
Several cancer immunotherapy approaches have been recently introduced into the clinics and they have shown remarkable therapeutic potentials. The groundbreaking cancer immunotherapeutic agents function as a stimulant or modulator of the body immune system to fight against or kill cancers. Although targeted immunotherapies such as immune check point inhibitors (CTLA-4 or PD-1/PD-L1), DNA vaccination and CAR-T therapy are revolutionizing cancer treatment, the delivery efficacy can be further improved while their off-target toxicity can be mitigated through nanotechnology approaches. Recent research has demonstrated that nanotechnology has multifaceted role for (i) reeducating tumor associated macrophages (TAM) to function as tumor suppressor agent, (ii) serving as an efficient alternative for Chimeric Antigen Receptor (CAR)-T cell generation and transduction, and (iii) selective knockdown of Kras oncogene addiction by nano-Crisper-Cas9 delivery system. The function of host immune stimulatory signals and tumor immunotherapies can further be improved by repurposing of nanomedicine platform. This review summarizes the role of multifunctional polymeric, lipid, metallic and cell based nanoparticles for improving current immunotherapy.
Keywords: CAR-T; CRISPR-Cas9; CTLA-4 targeting; Cancer; Cytokine storm; Dendritic cell vaccine; Immunotherapy; Nanomedicine; PD-1/PDL-1 targeting; Tumor associated macrophages.
Copyright © 2018 Elsevier B.V. All rights reserved.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy.Eur J Immunol. 2019 Aug;49(8):1147-1152. doi: 10.1002/eji.201848058. Epub 2019 Jul 9. Eur J Immunol. 2019. PMID: 31270810 Review.
-
[Specific immunotherapies in the treatment of cancers].Bull Cancer. 2019 Jan;106(1):37-47. doi: 10.1016/j.bulcan.2018.12.007. Epub 2019 Jan 11. Bull Cancer. 2019. PMID: 30638899 Review. French.
-
Cell Fate Reprogramming in the Era of Cancer Immunotherapy.Front Immunol. 2021 Jul 21;12:714822. doi: 10.3389/fimmu.2021.714822. eCollection 2021. Front Immunol. 2021. PMID: 34367185 Free PMC article. Review.
-
Emerging Immunotargets and Immunotherapies in Prostate Cancer.Curr Drug Targets. 2016;17(7):777-82. doi: 10.2174/1389450117666160217123304. Curr Drug Targets. 2016. PMID: 26898309 Review.
-
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8. J Hepatol. 2018. PMID: 29427729
Cited by
-
Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment.Pharmaceutics. 2024 Sep 20;16(9):1228. doi: 10.3390/pharmaceutics16091228. Pharmaceutics. 2024. PMID: 39339264 Free PMC article. Review.
-
Current Trends and Innovative Approaches in Cancer Immunotherapy.AAPS PharmSciTech. 2024 Jul 24;25(6):168. doi: 10.1208/s12249-024-02883-x. AAPS PharmSciTech. 2024. PMID: 39044047 Review.
-
LncRNA-mediated cartilage homeostasis in osteoarthritis: a narrative review.Front Med (Lausanne). 2024 Feb 21;11:1326843. doi: 10.3389/fmed.2024.1326843. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38449881 Free PMC article. Review.
-
Improving DNA nanostructure stability: A review of the biomedical applications and approaches.Int J Biol Macromol. 2024 Mar;260(Pt 1):129495. doi: 10.1016/j.ijbiomac.2024.129495. Epub 2024 Jan 14. Int J Biol Macromol. 2024. PMID: 38228209 Review.
-
Unravelling the Drug Encapsulation Ability of Functional DNA Origami Nanostructures: Current Understanding and Future Prospects on Targeted Drug Delivery.Polymers (Basel). 2023 Apr 12;15(8):1850. doi: 10.3390/polym15081850. Polymers (Basel). 2023. PMID: 37111997 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous